Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ImmuPharma completes phase III Lupuzor study; on track to publish top-line data this quarter

The last of the 200 patients has had their final assessment and the data is now being processed and analysed
lupus poster
Lupus is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood

ImmuPharma PLC (LON:IMM) has completed the pivotal phase III study of its Lupuzor lupus treatment, leaving it on track to publish top-line data from the trial in the current quarter.

The last of the 200 patients has attended their final assessment and data from the trial is now being collected, checked and analysed.

READ: ImmuPharma says last patient dosed in Phase III clinical trial of lupus treatment, Lupuzor™

AIM-quoted ImmuPharma said Lupuzor demonstrated a “robust safety profile” during the 12 month long trial, in keeping with what was seen in the successful phase IIb study.

The phase III trial was what’s called a randomised, double-blind investigation, which means half the group were given the ImmuPharma drug, while the others will have received a placebo that has no impact on the condition.

Even the doctors will only have found out which group is which when the study finished.

ImmuPharma 'delighted' with study completion

“We are delighted to announce this major milestone for ImmuPharma in having completed on track this pivotal Phase III trial for Lupuzor,” said chief scientific officer Robert Zimmer.

“With the continued robust safety achieved over this trial, we look forward with continued confidence to reporting top line results of the study this Q1 2018.”

Following requests from both investigators and patients, ImuuPharma is also kicking off a ‘follow-up’ study which will allow eligible patients to continue to receive Lupuzor for another six months.

WATCH: Immupharma 'looking forward and planning for success' with Lupuzor

The results will be gathered as an ‘extension’ open label study – i.e. patients will know that they’re taking the drug – and will be independent of the original late-stage trial.

Debilitating disease

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.

According to the Lupus Foundation of America, around 1.5mln in the States have the condition, with 90% of those estimateed to be women.

Successful trial data will lead to ‘significant rerate’

Despite that rise, house broker Northland Capital reckons they’re probably worth 181p and likely significantly more if the data comes back positive.

“With the trial now complete and all patients successfully monitored, Lupuzor continues to demonstrate a strong safety profile,” said Northland analyst Vadim Alexandre.

“Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside.”

Alexandre added: “Finally, it is encouraging to see demand from patients for a follow-up study.”

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use